Nurix Therapeutics

NRIXPhase 2

Nurix Therapeutics is focused on discovering, developing, and commercializing small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Its core DELigase platform integrates expertise in E3 ligases, ubiquitination, and medicinal chemistry to create targeted protein degraders and inhibitors. The company has established strategic collaborations with major pharmaceutical partners like Gilead and Sanofi, and is progressing a robust pipeline of drug candidates, including its lead BTK degrader NX-5948 and CBL-B inhibitor NX-1607, through clinical development.

Market Cap

$1.5B

Employees

150-200

Focus

Biotech

NRIX · Stock Price

USD 14.43+0.52 (+3.74%)

Historical price data

AI Company Overview

Technology Platform

The DELigase platform is an integrated drug discovery engine that leverages DNA-encoded libraries (DEL) and deep expertise in E3 ubiquitin ligases to discover small molecule targeted protein degraders and E3 ligase inhibitors.

Pipeline Snapshot

8 drugs in pipeline

Drug	Indication	Stage
NX-5948	Chronic Lymphocytic Leukemia (CLL)	Phase 2
NX-2127	Chronic Lymphocytic Leukemia (CLL)	Phase 1
NX-5948	Healthy Volunteer	Phase 1
NX-5948 + Esomeprazole	Healthy Volunteer	Phase 1
IP + Matching Placebo	Healthy Volunteers	Phase 1

Funding History

Total raised: $373M

IPO$175MUndisclosedJul 23, 2020

Series C$120MEcoR1 CapitalJan 15, 2020

Series B$55MForesite CapitalJun 15, 2018

Series A$23MThird Rock VenturesJan 15, 2014

Opportunities

Nurix has significant growth opportunities in capturing share of the large BTK inhibitor market with a potentially superior degrader, expanding into autoimmune diseases, and leveraging its CBL-B inhibitor platform in the broad immuno-oncology space.

Its validated platform also creates opportunities for additional high-value partnerships.

Risk Factors

Key risks include clinical trial failures for its lead assets, intense competition in the protein degradation field, high cash burn rate requiring future financing, and dependency on strategic partners for a significant portion of its pipeline value and funding.

Competitive Landscape

Nurix competes with other targeted protein degradation companies like Arvinas, Kymera Therapeutics, and C4 Therapeutics. Its differentiation lies in its oral drug candidates, a platform capable of producing both degraders and inhibitors, and validated partnerships with major pharmaceutical companies.

Publications

Patents

Pipeline